Rigel Pharmaceuticals RIGL Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's accounts receivable?
- Rigel Pharmaceuticals (RIGL) reported accounts receivable of $49.95M in Q1 2026.
- How has Rigel Pharmaceuticals's accounts receivable changed year-over-year?
- Rigel Pharmaceuticals's accounts receivable increased by 20.2% year-over-year, from $41.55M to $49.95M.
- What is the long-term trend for Rigel Pharmaceuticals's accounts receivable?
- Over 5 years (2020 to 2025), Rigel Pharmaceuticals's accounts receivable has grown at a 26.5% compound annual growth rate (CAGR), from $15.97M to $51.76M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.